From vineyards to antivirals, Gilly Regev brings creative thinking to science
PharmaVoice
JUNE 27, 2022
The CEO of SaNOtize is tapping into outside-the-box innovation to develop a nitric oxide-delivery platform to treat and prevent COVID-19.
Mon.Jun 27, 2022
279 
Dengue Vaccine: What Pharmacists Need to Know
Pharmacy Times
JUNE 27, 2022
The FDA approved the first vaccine for dengue disease in May 2019.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
A myriad of blows: Who's getting hit the hardest by the economy's troubles
PharmaVoice
JUNE 27, 2022
The downturn shows few signs of hurting large pharma, but small biotechs and generics makers could face a credit crunch.
Research Shows Improved Treatment Options for Heart Defect Prevention Before Birth
Pharmacy Times
JUNE 27, 2022
The researchers noted that new therapies have faced challenges because of this knowledge gap in CHD.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
GSK hepatitis B hope bepirovirsen heads for phase 3 test
pharmaphorum
JUNE 27, 2022
An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV) in a mid-stage trial, setting up a phase 3 assessment next year to see if it could offer a “functional cure” for the widespread disease. Interim results from the phase 2b B-Clear showed that bepirovirsen reduced levels of hepatitis B surface antigen (HBsAg) and HBV DNA after 24 weeks’ treatment to below the lower limit of detection in people with chronic hepatitis B, raising hopes
Vaccine Candidate Shows Efficacy Against Omicron with COVID-19 Beta-Containing Vaccine
Pharmacy Times
JUNE 27, 2022
The Sanofi-GSK vaccine demonstrated a favorable safety and tolerability profile throughout stage 1 and stage 2 of the VAT08 trial, according to the researchers.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
Current Standards of Care in Platinum-Resistant Ovarian Cancer
Pharmacy Times
JUNE 27, 2022
Folate receptor ? may be an important treatment target for ovarian tumors.
Global Blood Therapeutics: driving innovation in sickle cell disease
European Pharmaceutical Review
JUNE 27, 2022
Sickle cell disease – a rare, yet prevalent, genetic disease in Europe. Sickle cell disease (SCD) is a devastating, lifelong blood disorder that occurs when someone inherits sickle cell genes from both parents. 1 It affects haemoglobin, a protein carried by red blood cells that delivers oxygen throughout the body. 2 SCD predominantly affects those whose ancestors are from sub-Saharan Africa but is also common in people of Hispanic, South Asian, Southern European and Middle Eastern ancestry. 3 Wh
FDA Approves Lisocabtagene Maraleucel for Second-Line Large B-cell Lymphoma
Pharmacy Times
JUNE 27, 2022
Lisocabtagene maraleucel (liso-cel, Breyanzi; Bristol Myers Squibb) approved for the second-line treatment of patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma not otherwise specified, high-grade B-cell lymphoma, primary mediastinal LBCL, and follicular lymphoma grade 3B.
Pursuing new paths in targeted protein degradation drug development
European Pharmaceutical Review
JUNE 27, 2022
DRUG DEVELOPMENT based on targeted protein degradation (TPD) has progressed rapidly since the publication in 2015 of three landmark papers 1-3 that highlighted important early-stage breakthroughs with drug-like molecules in this area of research. Since that time, the field has advanced to the point where there are now more than two dozen companies dedicated to working on the development of TPD drugs, some of which have advanced to later-stage clinical development.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacists Can Help Create a Safe, Tolerant Workplace for LGBTQ+ Employees
Pharmacy Times
JUNE 27, 2022
As we mark the second anniversary of Bostock v. Clayton County this month, let’s remember to treat each other with dignity, empathy, and respect, while we work together for a safer and more tolerant workplace.
BMS receives US FDA approval for CAR T cell therapy to treat B-cell lymphoma
Pharmaceutical Technology
JUNE 27, 2022
Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for its CD19-directed chimeric antigen receptor (CAR) T cell therapy Breyanzi (lisocabtagene maraleucel) to treat relapsed or refractory large B-cell lymphoma (LBCL) in adult patients. Breyanzi is given as a defined composition for reducing the variability of the CD8 and CD4 component dose.
Study Break: The Importance of Fellowship Opportunities and the Community Pharmacy Fellowship from NCPA, CPESN
Pharmacy Times
JUNE 27, 2022
We spoke with Carlie Traylor, PharmD, of the National Community Pharmacy Association to learn about a fellowship program offered by NCPA and CPESN.
Drug Development In-Depth Focus 2022
European Pharmaceutical Review
JUNE 27, 2022
Pursuing new paths in targeted protein degradation drug development. Targeted protein degradation (TPD) therapy has grown rapidly as a field, with transformational potential. TPD is poised to be successful in delivering marketed products, but limitations are now starting to emerge, including tumour resistance, a lack of mechanisms for oral dosing, and the inability to penetrate tissues such as the CNS.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
AbbVie Submits sNDA to FDA for Qulipta for Preventive Treatment of Chronic Migraine
Pharmacy Times
JUNE 27, 2022
Submission is based on phase 2 study results evaluating atogepant in adults who met the primary endpoint of a statistically significant reduction from the baseline compared with a placebo.
Sanofi pushes to accelerate medical writing, reporting processes
Outsourcing Pharma
JUNE 27, 2022
The pharmaceutical company has enlisted the help of the AI and NLP tech specialist to streamline clinical study report generation and submission processes.
Rapid method development to overcome challenges of bi-specific antibody purification
European Pharmaceutical Review
JUNE 27, 2022
With expanding biologics pipelines encompassing an increasingly diverse range of new molecular formats, the therapeutic potential of bi-specific antibodies (bsAbs) continues to receive widespread interest. 1 The majority of bsAbs consist of three or more light chain (LC) and heavy chain (HC) combinations and have the advantage of simultaneously binding two antigens via different epitopes on each antigen-binding fragment (Fab) arm ( Figure 1 ).
BioMarin gene therapy for haemophilia on course for EU approval
pharmaphorum
JUNE 27, 2022
The EMA’s human medicines advisory committee has recommended that BioMarin Pharmaceutical’s haemophilia A gene therapy Roctavian be approved in the EU, removing one of the last barriers to launch. The CHMP backed a conditional marketing authorisation for Roctavian (valoctocogene roxaparvovec or valrox) for severe haemophilia A in adults without inhibitors – antibodies that make standard Factor VIII replacement medicines less effective.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Alexion to expand biologics manufacturing with €65m investment
European Pharmaceutical Review
JUNE 27, 2022
Alexion , AstraZeneca’s Rare Disease group, will invest €65 million to enhance its production capabilities in Ireland. The investment will help the company scale up its biologics manufacturing capacity and expand R&D efforts over the next 18 months. The money will go towards the installation of new drug substance production equipment and warehousing facilities to support ambient and cold storage at two sites: College Park in Blanchardstown and Monksland Industrial Park in Athlone.
How the US’s pending PIE Act will improve patient access to medication
pharmaphorum
JUNE 27, 2022
Jennifer Mathieu, director of government relations at the Academy of Managed Care Pharmacy (AMCP), tells us why the organisation backed the pre-approval information exchange (PIE) Act of 2022 and how the legislation will empower companies to share information with healthcare payers and plans during the FDA approval process. . The AMCP backed bill (H.R. 7008), which allows manufacturers to share vital information with healthcare payers and plans while treatments are pending Food and Drug Admini
Janssen invests $5m in Stand Up To Cancer’s health equity effort
Outsourcing Pharma
JUNE 27, 2022
The sponsorship from Janssen Pharmaceutical Companies will be used by the cancer support network to boost diversity in Phase I and Phase 2 clinical trials.
Cryoport and Cell Matters to Collaborate on Standardizing Cell Therapy Supply Chain processes
Pharmaceutical Commerce
JUNE 27, 2022
Companies hope to combine their cryobiology expertise with dedicated packaging and supply chain services.
June 27 is National HIV Testing Day
Pharmacy Times
JUNE 27, 2022
June 27 is National HIV Testing Day, so Pharmacy Times® sat down with Brad McElya, PharmD, director of Specialty Health Solutions at Walgreens, to discuss the importance of HIV testing.
Cybersecurity hiring levels in the pharmaceutical industry rose in May 2022
Pharmaceutical Technology
JUNE 27, 2022
The proportion of pharmaceutical companies hiring for cybersecurity related positions rose in May 2022 compared with the equivalent month last year, with 46.8% of the companies included in our analysis recruiting for at least one such position. This latest figure was higher than the 39.4% of companies who were hiring for cybersecurity related jobs a year ago and an increase compared to the figure of 43.6% in April 2022.
Daily OTC Pearl: All Natural Acid Indigestion Relief
Pharmacy Times
JUNE 27, 2022
Maty's All Natural Acid and Indigestion Relief is an alternative to traditional antacid tablets to relieve indigestion and heartburn.
Ipsen to buy biopharmaceutical company Epizyme for $247m
Pharmaceutical Technology
JUNE 27, 2022
Ipsen has signed a definitive merger agreement to acquire all the outstanding shares of commercial-stage biopharmaceutical company Epizyme, for an initial total consideration of $247m. The company will begin an all-cash tender offer through its subsidiary to buy Epizyme’s all outstanding shares for $1.45 per share in cash along with a contingent value right (CVR) of $1.00 for each share.
Daily Medication Pearl: Venlafaxine Extended-Release (Effexor XR)
Pharmacy Times
JUNE 27, 2022
Venlafaxine Extended-Release (Effexor XR) is indicated for the treatment of major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder.
Turning Point Therapeutics and MD Anderson collaborate to advance cancer therapies
Pharmaceutical Technology
JUNE 27, 2022
Turning Point Therapeutics has entered a strategic research and development alliance with the University of Texas MD Anderson Cancer Center (MD Anderson) to advance the evaluation of two of its investigational small molecules for precision cancer treatments. The focus of this strategic alliance will be on drug candidates, repotrectinib and elzovantinib (TPX-0022).
New Recommendations Show How to Use Genetic Testing to Prevent Sudden Cardiac
Pharmacy Times
JUNE 27, 2022
Clinical evaluation dictates the need for preventive therapy and advice on exercising and participation in competitive sports, according to the European Society of Cardiology.
Top Resources for the Sleep Medicine Board Exam
Board Vitals - Pharmacist
JUNE 27, 2022
The ABIM Sleep Medicine board exam is a notoriously difficult test, with a pass rate of just 88% in 2021. As you study for the Sleep Medicine boards, you are likely wondering which preparation books and courses are worth your time, energy and money. We’ve compiled the best time-tested Sleep Medicine resources to help you get ready for test day. The BoardVitals Sleep Medicine Question Bank is a great resource for board review questions.
Oncology Overview: Lenvatinib (Lenvima) for Multiple Cancer Types
Pharmacy Times
JUNE 27, 2022
Lenvima (lenvatinib) is approved for the treatment of thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma.
Well-Being Survey Discussion: Alex Barker and Mike Koelzer
The Happy PharmD
JUNE 27, 2022
Well Being Report: Are Pharmacists going crazy? Listen to the full episode at the link below: [link] . . Pharmacist well-being: Changes Post-COVID-19. 78% of Pharmacists say they are not happy at work Post COVID-19 Pandemic. Many surveys conducted before COVID among pharmacists showed that many pharmacists were not happy with their jobs. In one of such studies by Drug Topics® in 2020, 7 out of 10 pharmacists revealed they were not happy with their jobs.
Regulators Seek More Drug Effects Research Related to Pregnancy, Lactation
PharmExec
JUNE 27, 2022
Amid push to include this population more in clinical trials, the goal is to uncover improved evidence on the risks/benefits of drugs for these patients.
Let's personalize your content